Showing results (2501-2510 of 2,573) with videos related to
Sort By:
Pageof 258
Cancer Discovery|April 11, 2022
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsMengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, et al.Pharmacoepidemiology and Drug Safety|November 25, 2024
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung CancerConnor B Grady, Wei-Ting Hwang, Joshua E Reuss, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab GovitecanJhanelle E Gray, Rebecca S Heist, Alexander N Starodub, et al.JTO Clinical and Research Reports|September 6, 2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) TrialsScott N Gettinger, Rudolf M Huber, Dong-Wan Kim, et al.The New England Journal of Medicine|September 30, 2014
Crizotinib in ROS1-rearranged non-small-cell lung cancerAlice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2017
Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional AnalysisWilliam J Magnuson, Nataniel H Lester-Coll, Abraham J Wu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2022
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid TumorsTae Won Kim, Howard A Burris, Maria J de Miguel Luken, et al.The Lancet. Oncology|September 22, 2011
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisAlice T Shaw, Beow Y Yeap, Benjamin J Solomon, et al.The Lancet. Oncology|September 3, 2013
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO groupNancy U Lin, Jeffrey S Wefel, Eudocia Q Lee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2019
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung CancerJulia K Rotow, Philippe Gui, Wei Wu, et al.Pageof 258